Tag: Academic research

For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into different organ systems, flares without warning, and leaves cumulative damage in its wake. More than three million people worldwide live inside that uncertainty, navigating cycles of remission and relapse that can erode health over time. Treatments have advanced, but slowly and often not far enough to fundamentally change the trajectory of disease.

Genentech’s obinutuzumab (marketed as Gazyva) is gaining regulatory momentum after submitting a supplemental Biologics License Application (sBLA) to expand its use into SLE, as it repurposes an established immuno-oncology biologic therapy. The U.S. Food and Drug Administration (FDA) is expected to make a decision by the end of 2026 on the label expansion for obinutuzumab, which was first approved on November 1, 2013, for treating previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil.

The ALLEGORY trial

SLE is not a single-pathway disease. It is a systemic autoimmune condition in which the immune system misfires, attacking healthy tissues across the body. Skin, joints, blood vessels, and vital organs, particularly the kidneys, can all be affected by the disease. In roughly half of patients, lupus nephritis develops within five years of diagnosis and significantly increases the risk.

B cells, a type of white blood cell that makes antibodies, are at the heart of this problem. In lupus, these cells generate autoantibodies that target the body’s own structures, triggering chronic inflammation. Over time, repeated flares can lead to irreversible organ damage.

Even diagnosing lupus can be a challenge. Its symptoms mimic those of other diseases, and its presentation varies widely from patient to patient. Delays of two to six years are common, time during which the disease can quietly progress. Against this backdrop, the need for therapies that do more than manage symptoms and actually alter disease biology has become increasingly pressing.

That urgency is what makes the Phase III ALLEGORY trial so consequential. Designed as a randomized, double-blind, placebo-controlled study, ALLEGORY evaluated obinutuzumab in adults with active SLE who were already receiving standard therapy. The goal was not just to see if the drug worked, but to measure whether it could meaningfully shift disease outcomes.

The primary endpoint was the SLE Responder Index 4 (SRI-4), a composite metric that captures improvement across multiple dimensions of disease activity. At 52 weeks, 76.7% of patients receiving obinutuzumab attained an SRI-4 response, in contrast to 53.5% in the placebo group. That difference is both statistically significant and clinically meaningful, representing a substantial improvement in disease control.

In addition, patients treated with obinutuzumab experienced fewer disease flares, reduced reliance on glucocorticoids, and higher rates of remission. In fact, remission rates more than doubled compared to placebo. A greater proportion of patients also reached consistent, low disease activity states, an increasingly important benchmark for a disease defined by unpredictability.

Precision over suppression

What sets obinutuzumab apart is not just its efficacy but how it works. Traditional lupus therapies often rely on broad immunosuppression to dampen the immune system as a whole to control inflammation. While this approach can be effective, it comes with trade-offs, including increased susceptibility to infections and long-term toxicity.

Obinutuzumab takes a more targeted route. It is a glycoengineered, type II anti-CD20 monoclonal antibody designed to bind to a protein expressed on the surface of certain B cells. Once attached, it triggers both direct cell death and enhanced immune-mediated cytotoxicity, leading to potent depletion of the B cells that drive lupus pathology. This dual mechanism allows for a more precise intervention by focusing on the source of disease activity rather than suppressing the immune system indiscriminately. The distinction is more than technical. It represents a broader shift in immunology toward therapies that are not only effective but also strategic.

Regarding safety risk, the data from ALLEGORY offers reassurance. Adverse events were somewhat more frequent in the treatment group, but the overall safety profile remained consistent with what is already known about the drug. Importantly, no new safety signals were identified. In context, the benefit-risk balance appears favorable, particularly given the magnitude of clinical improvement observed. For clinicians, that balance is critical. Lupus is a chronic disease that often requires long-term management, making tolerability as important as efficacy.

If approved for SLE, obinutuzumab would become the first anti-CD20 therapy specifically indicated for the condition, a milestone that could reshape the treatment landscape. It would also expand a therapeutic arsenal that has remained limited for far too long. Despite decades of research, only a small number of therapies have been approved for lupus, so many patients have limited options.

For patient advocates, the significance is immediate and tangible. Albert T. Roy, president and CEO of the Lupus Research Alliance, emphasized both the burden of disease and the promise of new treatments. “The filing submission for Gazyva is a significant step and could provide another treatment option for people with systemic lupus erythematosus (SLE),” Roy told Inside Precision Medicine. “With only two approved therapies for SLE, the potential availability of another option is significant.”

Obinutuzumab enters a field that is changing quickly, with new technologies expanding the possibilities of immune-targeted therapies. Among the most promising are CAR T-cell therapies. They’re also on the far end of the complexity scale, especially as autologous therapies, which involve the extraction of a patient’s T cells, genetically engineering them to target specific immune cells, and reinfusing them into the body. Early studies in lupus have shown intriguing results.

But there are practical limitations. CAR T-cell therapies are resource-intensive, requiring specialized manufacturing, inpatient care, and significant infrastructure. They remain in early-stage trials for lupus and are not yet widely accessible.

The way Roy sees it, monoclonal antibodies like obinutuzumab offer a different path that balances innovation with scalability. “Both approaches target B cells—drivers of lupus pathogenesis—but they work differently,” explained Roy. “Monoclonal antibodies like Gazyva are easier to scale and administer to patients in an outpatient setting, making them more accessible and cost-effective. CAR T immunotherapies, by contrast, require a more complex manufacturing process, as well as inpatient care to prepare the patient for the CAR T infusion. Additionally, CAR T immunotherapies are in early-phase clinical trials, where safety and efficacy are still being evaluated in lupus.”

Reconsidering SLE standard of care

The accessibility of obinutuzumab could prove definitive. Even if approved, obinutuzumab will not automatically transform lupus care. Several challenges remain. Awareness is one. Both patients and healthcare providers need to understand where this therapy fits and who is most likely to benefit. Access is another. As with many biologic therapies, cost and insurance coverage will play a significant role in determining availability.

Then there is the question of personalization. Lupus is a heterogeneous disease, and responses to treatment can vary widely. Identifying biomarkers or clinical characteristics that predict response to B-cell depletion will be essential for helping clinicians improve outcomes.

“The biggest challenges are awareness, education, and access,” said Roy. “If approved by the FDA, patients and providers need to know that this therapy could be an option and understand who may benefit most from it. Given the heterogeneity of lupus, Gazyva might not work for everyone, but having another option would be a big win for patients and their providers.

The emergence of obinutuzumab reflects a broader transformation in lupus research and care. The field is moving away from a reactive model, treating flares as they occur, toward a proactive one aimed at preventing them altogether. There is growing emphasis on reducing or eliminating long-term steroid use, which has long been a cornerstone of lupus treatment but carries significant side effects. At the same time, researchers are exploring combination strategies and new therapeutic targets, building on the foundation of B-cell biology.

The ultimate goal is ambitious but increasingly plausible: sustained remission, potentially even without ongoing therapy. “We’re excited about the potential of Gazyva to build on what’s been shown in lupus nephritis and extend those benefits to a broader lupus population,” Roy said. “Looking ahead, we hope the field continues to shift from broad immunosuppression to targeted therapies, with a continued focus on reducing reliance on steroids and, ultimately, achieving drug-free remission.

Obinutuzumab does not solve lupus. It does not eliminate the complexity of the disease or the challenges that come with it. But it does signal something important: progress that is measurable, meaningful, and potentially transformative. For patients who have long navigated a landscape of limited options and uncertain outcomes, that progress matters. It offers not just another treatment but a different kind of treatment grounded in precision, backed by strong clinical data, and designed with real-world use in mind.

If the regulatory path leads to approval, obinutuzumab could mark the beginning of a new chapter in lupus care defined less by compromise and more by control. And for a disease that has long resisted both, that shift may be the most powerful development yet.

 

The post FDA Accepts Label Expansion of Immuno-Oncology Drug to Lupus appeared first on Inside Precision Medicine.

Researchers at the University of Houston, working with collaborators at Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, have identified a mechanism that identifies epithelial cell stress as a one of the main drivers of Crohn’s disease, a finding that runs counter to much current thinking of Crohn’s disease as immune-mediated and instead frames it as a failure of within the intestinal barrier. The study, published in Gastro Hep Advances, shows that chronic integrated stress response (ISR) activation and a related cell death pathway, necroptosis, form a feedback loop that damages intestinal epithelial cells and prevents cell regeneration leading to sustained inflammation.

“It’s a paradigm shift from the way we’ve thought about the disease,” said senior author Seema Khurana, PhD, a professor of biology and biochemistry at the University of Houston. “Existing therapies primarily manage symptoms because we don’t know what causes the disease. We believe our research brings us closer to identifying those drivers.”

Crohn’s disease is typically treated with anti-inflammatory therapies aimed at suppressing immune activity, but only a minority of patients have long lasting benefits. This current study may help explain why anti-inflammatories only have limited benefits by showing that intestinal barrier dysfunction is not simply a consequence of inflammation but is a factor in disease development.

For their research, the team sought to discover how stress signaling within certain epithelial cells contribute to disease progression. The ISR is a conserved cellular pathway that helps cells respond to stress by temporarily reducing protein production and activating processes that restore cellular balance, including stress-response gene expression, protein quality control, and metabolic adaptation. While short-term ISR activation is a temporary response to cellular stress, the researchers found that in Crohn’s disease, ISR signaling becomes chronically activated.

“Our results identify ISR activation as a unifying hallmark of epithelial stress in CD, regardless of whether the initiating insult is intrinsic (loss of villin-1/gelsolin) or extrinsic (TNF-α dysregulation),” the researchers wrote.

The result of this chronic ISR activation is that instead of helping epithelial cells become healthy, they are instead kept in a dysfunctional state. This leads to mitochondrial stress and triggers necroptosis, a form of programmed cell death that releases inflammatory signals. The combination of ongoing stress signaling and cell death prevents epithelial regeneration and weakens the intestinal barrier, allowing microbes to infiltration tissue in the intestine further increasing inflammation.

Prior studies have focused on this form of dysfunction to Crohn’s disease, but ISR activation had not been clearly characterized as a central driver of disease development. To address this, the team used a number of different models of Crohn’s disease, including genetically engineered mice with epithelial-specific ISR activation, mice with chronic inflammation driven by TNF-α dysregulation, and patient-derived intestinal organoids. The organoids allowed the researchers to directly study human epithelial responses.

The resulting data showed that for all the models, the same pattern of chronic ISR activation, increased necroptosis, impaired epithelial survival, and failure of regenerative growth emerged.

To begin finding potential therapeutic approaches based on these new findings, the investigators then tested whether blocking these pathways could reverse intestinal damage. Using both experimental inhibitors and two FDA-approved cancer drugs, pazopanib and ponatinib, repurposed at low concentrations, they were able to suppress ISR signaling and necroptosis. This restored epithelial cell survival, improved regeneration, and reestablished barrier integrity.

“A major advance of this work is the demonstration that pharmacologic inhibition of ISR or necroptosis restores epithelial homeostasis by promoting regenerative growth of the epithelium in both murine and human models of CD,” the researchers wrote.

If additional studies can establish ISR inhibition as safe and effective for human use, this research could be the beginning of a shift in how Crohn’s disease is treated. Instead of focusing only on controlling inflammation, a new class of treatments could aim to repair the epithelial barrier directly. This approach aligns with emerging evidence that permeability barrier healing is a stronger predictor of long-term remission than traditional measures such as mucosal healing.

Further, because both pazopanib and ponatinib are already approved drugs that are known to be safe and have well characterized pharmacology profiles, the path to these new treatments could be on a fast track.

“If you had to start from scratch to identify and develop a drug, it takes 10 to 15 years and can cost between $1 billion to $2 billion,” Khurana said. “For a patient who is suffering from chronic Crohn’s disease, they’re looking for some immediate relief. Our goal was to make our findings much more translatable to real patients.”

Beyond drug development, the study points to new opportunities for improving clinical care. Biomarkers of ISR activation, such as phosphorylated eIF2α or RIPK3 expression, could help identify patients with barrier dysfunction and guide treatment decisions. Patient-derived organoid systems may also enable personalized testing of therapeutic responses before treatment.

The post Restoring Gut Barrier Function in Crohn’s by Targeting ISR Activation appeared first on Inside Precision Medicine.